Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Phathom measures out IPO terms
Takeda is set to emerge with almost 26% of Phathom Pharmaceuticals, which has licensed one of its gastrointestinal disease drugs, and which is targeting $158m.
Tela Bio tells of $69m IPO filing
ProMedica and Pacira are both in line for exits after surgical implant producer Tela Bio filed for an initial public offering.
Vir Bio rides to $143m in IPO
SoftBank Vision Fund-backed immunology therapy developer Vir will float at the bottom of its range, having raised in excess of $820m in VC funding in roughly three years.
Fangdd looks to capture $150m in IPO
Online real estate marketplace Fangdd has filed for a $150m initial public offering that would allow Shanying International to exit.
BioNTech binds itself to public markets
The Eli Lilly, Pfizer and Sanofi-backed cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.
Aprea closes $97.8m IPO
The underwriters for Praktikertjänst-backed Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.
ADC abandons IPO plans
The AstraZeneca-backed cancer drug developer had hoped to raise up to $212m in a US flotation but is instead pulling back due to unfavourable market conditions.
PropertyGuru proposes $257m in shares for IPO
Emtek is set to sell up to $55m of its shares in online real estate platform PropertyGuru in an Australian initial public offering that could bring in up to $257m in proceeds.

Other News

Viela Bio peels off $150m in IPO
AstraZeneca spinoff Viela Bio has gone public in an offering that involved existing backers buying some $70m worth of stock, and its share price has since risen 21.7%.
Aprea collects $85m in IPO proceeds
Praktikertjänst-backed Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.
Frequency attracts $84m in IPO
The Alexandria Real Estate Equities-backed regenerative medicine developer floated at the bottom of its range while cutting the number of shares.
4D Molecular files for $100m IPO
The Pfizer and Chiesi-backed gene therapy developer plans to use the IPO proceeds to advance treatments for Fabry disease, cystic fibrosis and ophthalmological diseases.
36Kr breaks IPO news
Ant Financial and Nikkei will have the chance to exit Chinese media and startup services provider 36Kr, which has filed for a $100m initial public offering in the US.
Beam Therapeutics threads its way toward public markets
The GV-backed genomic editing technology developer has filed to raise up to $100m, adding to some $225m of venture funding in under three years.

Editor's Picks

Peloton pulls itself to billion-dollar IPO
Comcast NBCUniversal and Grace Beauty scored exits as Peloton Interactive floated at the top of its range to raise $1.16bn, getting a further $100m in a private placement.
Cloudflare clocks up $525m in IPO
Alphabet, Baidu, Microsoft and Qualcomm all notched up exits as the cloud services provider floated above a range that had already been increased.
Megvii makes for Hong Kong to IPO
The Alibaba and Foxconn-backed facial-recognition technology developer has filed for an offering that is reportedly set to raise $500m to $1bn.
test reg